| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,019,785 | -11,757,127 |
| Stock-based compensation expense | 1,441,152 | 996,505 |
| Change in fair value of warrants | -438,000 | -418,000 |
| Prepaid expenses and other current assets | -1,471,155 | 950,568 |
| Accounts payable | -193,948 | -1,331,663 |
| Accrued expenses | 46,758 | 255,800 |
| Net cash used in operating activities | -16,692,668 | -13,205,053 |
| Proceeds from issuance of common stock, net | 21,427,151 | 19,783,423 |
| Net cash provided by financing activities | 21,427,151 | 19,783,423 |
| Net increase in cash and cash equivalents | 4,734,483 | 6,578,370 |
| Cash and cash equivalents at beginning of period | 10,551,916 | - |
| Cash and cash equivalents at end of period | 15,286,399 | - |
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)